Silica as a Rheology Modifier: How It Controls Viscosity and Flow

Published: Source: Silica Raw Materials News Section: Silica Raw Materials

📌 Key Takeaways

  • Topic: Silicon Dioxide Supplier: How to Choose the Right Grade and Reliable Partner
  • Keywords: silica market size
  • Published: 2026-11-20 05:30:33
  • Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
In recent years, mesoporous silica nanocarriers have attracted great interest in pharmaceutical science because of their advantageous properties. Straightforward synthesis, low production cost, and tunable physicochemical properties characterize them. Their behavior in the human body, including targeting possibilities, can be influenced by particle size, particle morphology, pore size, internal structure, and surface chemistry. By modifying the surface functional groups and the surface charge, targeted therapy is achievable in several medical conditions. A wide range of drug loading methods is available (whether solvent-based or solvent-free techniques), so the most appropriate method can be selected, and higher drug concentration can be encapsulated, enhancing loading efficiency. Nevertheless, their formulation for different delivery routes, such as dermal, pulmonary, or the most favorable oral administration, is very difficult due to their large particular surface, adhesivity, and low density, which leads to poor powder flow properties, posing a huge difficulty in the manufacturing and formulation of solid dosage forms. Agglomeration of the particles by granulation or pelletization is a brilliant remedy for enhancing flowability. Concluding this, the granulation process of mesoporous silica has to be investigated and optimized to sustain the initially high porosity and high particular surface area of the material.

Silica for Wafer Polishing: Slurry Types, Particle Size and Performance

Silicon Dioxide Side Effects: What You Need to Know
Even though MSNs can usually be recognized as secure products, their use during therapy may cause side impacts in the body [ 1, 2, 29 ]. Due to their small size and large surface area, they may tend to accumulate in the body, or certain organs (liver, spleen, kidney, lung) and may even be toxic in higher concentrations, which is a clear disadvantage [ 1, 4, 27 ]. The silanol groups (Si-OH) on their surface can interact with the phospholipid layer of the cell membrane, thereby causing cell lysis or, in extreme cases, hemolysis [ 4, 8 ]. In severe cases, the lack of hemocompatibility can also cause issues [ 2 ]. Overall, indications of cytotoxicity, haemotoxicity, and genotoxicity were also found [ 4, 8 ]. That is why the biocompatibility of all comparable preparations must be strictly controlled [ 2, 4, 27 ]. The physicochemical features (particle size, particle morphology, surface chemistry, pore structure, etc.) of nanocarriers also have a major impact on toxicity [ 2, 4, 8, 30 ]. Additionally, further attention must be paid to the biological influences of their decomposition products, because they may also cause unwanted side influences [ 1 ]. The breakdown of silica nanoparticles in the body can take up to a few days. The opening hydration is followed by hydrolysis, and, in the end, they are excreted in the urine in the form of silicic acid [ 1 ]. Nevertheless, the literature is contradictory in this regard [ 31 ]. Some experiments show no considerable cytotoxic effect [ 18, 31 ], while other experiments say otherwise [ 23, 32 ]. For example, an in vitro study was performed with multiple concentrations, surfaces, and particle sizes (60 nm, 100 nm, 300 nm) of MSNs, with an exposure time of 72 h [ 18 ]. This study shown no significant cytotoxic influence in any of the cell lines tested (human cervical (HeLA), epithelial lung (A549), and glioblastoma (U251)) [ 18 ]. Ismail et al. investigated the cytotoxic effect of silica nanoparticles in vivo in mouse models [ 33 ]. Amorphous silica nanoparticles were administered to the animals orally, at a dose of 150 mg/kg/day, for 3 months. Based on these mouse models, no toxic effects were detected under sub-chronic treatment of the nanoparticles [ 31 ]. In another study, particle size (15 nm, 60 nm, 200 nm) dependent impact was observed on cellular viability in all four cell lines tested (THP-1 derived macrophages, A549 epithelial cells, HaCaT keratinocytes, and NRK-52E kidney cells) [ 23 ]. Smaller particles caused notable toxicity on each cell line, after the exposure time of 24 h, in contrast to the larger particles, which demonstrated no cytotoxic impact [ 23 ]. A comparable outcome has been published to verify the toxic characteristic of mesoporous silica. In this in vitro study, the researchers investigated the effect of MSNs with an average size of 7 nm on cell viability at three different concentrations. After 72 h of exposure, only the highest concentration (62.5 µg/mL) caused a substantial decrease in cell viability of human lung fibroblast cells. This toxicity occurred in a time- and dose-dependent manner [ 32 ]. In an in vivo mouse model, MacCuaig et al. presented coating-dependent impacts after repeated intravenous administration of MSNs. Chitosan-coated MSNs induced minor organ changes and were the most biocompatible. Uncoated and especially PEG-coated MSNs (especially 2K PEG) moderately augmented pre-existing vascular or organ lesions, implying that PEGylation has the potential to augment chronic risks, while chitosan enables safer long-term use [ 34 ]. An in vitro study of Barguilla et al. exposed epithelial lung cells to bare, PEG-functionalized, or galacto-oligosaccharide-functionalized MSNs for eight weeks. There was no reported long-term DNA damage, but malignant-like alterations like anchorage-independent growth, boosted migration/invasion, and secretome-facilitated tumor promotion were triggered by PEG- and GAL-functionalized MSNs. Naked MSNs did not cause such alterations and were determined to be safer [ 35 ]. Coating, on the whole, exerts a significant impact on the safety of MSNs. Uncoated MSNs are relatively innocuous; the most biocompatible coatings were achieved with chitosan, but PEG and carbohydrate functionalization can be dangerous in the long run, from vascular toxicity in vivo to tumor-promoting activity in vitro [ 34, 35 ].
Silica OEM: How Private-Label and Custom Silica Manufacturing Works
78. Guo X., Zhang C., Bai Y., Che Q., Cao H., Guo J., Su Z. Synthesis of Chitosan Oligosaccharide-Loaded Glycyrrhetinic Acid Functionalized Mesoporous Silica Nanoparticles and In Vitro Verification of the Treatment of APAP-Induced Liver Injury. Molecules. 2023;28:4147. doi: 10.3390/molecules28104147. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ]
Silica Aerogel Blanket: Thermal Conductivity, Thickness Options and Insulation Uses
What Is an Antiblock Agent for Film? How Silica Prevents Film Blocking

Silica Supplier Korea: Key Producers, Demand Sectors and Import Options

What is silica (SiO₂)?

silica for adhesives

What is the difference between fumed silica and precipitated silica?

silica supplier Indonesia 35. Barguilla I., Candela-Noguera V., Oliver P., Annangi B., Díez P., Aznar E., Martínez-Máñez R., Marcos R., Hernández A., Marcos M.D. Toxicological Profiling and Long-Term Influences of Bare, PEGylated- and Galacto-Oligosaccharide-Functionalized Mesoporous Silica Nanoparticles. Int. J. Mol. Sci. 2023;24:16158. doi: 10.3390/ijms242216158. [ DOI ] [ PMC free post ] [ PubMed ] [ Google Scholar ]

What drives silica raw material prices?

silica reinforcing filler No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Cite this article: Silica Raw Materials News. "Monodisperse Silica Spheres: Size Control, Synthesis and Applications ." Published 2026-11-20 05:30:33. /news/article.html
Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.